Top Trending Tickers On StockTwits For March 4

Here's a look at the top tickers trending on StockTwits.com. S&P 500 futures: Pre-market boost from calming tensions Investors woke up to news that Russian President Vladimir Putin has ordered troops who took part in a military exercise across central and western Russia back to their bases. The likelihood of the tense situation in Ukraine escalating even further appears to be less likely. The news has jolted U.S. stock futures in addition to cooling off oil and gold prices. Spdr S&P 500 SPY followed other international markets and traded in positive territory. The Stoxx 50 was seen trading higher by 2.2 percent and Russia's Micex was up more than five percent. Shares of the index ETF were trading higher by 0.92 percent in the pre-market session. Oxygen Biotherapeutics: Investors bullish following company update Oxygen Biotherapeutics OXBT announced that it has been notified by the U.S. Food and Drug Administration that it has completed a review of the company's nonclinical submission of Oxycyte. The FDA has lifted its clinical hold which allows the company to proceed with the clinical development program in the U.S. Oxycyte, when used as an intravenous emulsion carries as much as five times more oxygen than hemoglobin, making the therapy a potential superior method of transporting oxygen to tissues and carrying carbon dioxide to the lungs for disposal. Shares were trading higher by 31.13 percent in the pre-market session. Molycorp: Losses continues on lower revenue Last night, Molycorp MCP reported its fourth quarter results. The company announced an EPS of -$0.28, beating the consensus estimate of -$0.29. Revenue of $123.8 million missed the consensus estimate of $148.22 million. Net loss for the quarter totalled $194.3 million, compared with a loss of $359.6 million in the same quarter last year. Revenue in the quarter declined 17 percent year over year which was attributed to a shifting product mix and lower prices for rare earth minerals and low volumes of its magnetic powders. Molycorp said that it had achieved a “significant” milestone with the completion of commissioning and the operational start-up of its Chlor-Alkali plant at its Mountain Pass, California rare earth facility. "Putting our Chlor-Alkali plant into operation is a major milestone. Producing our own chemical reagents and reducing our water discharge will lower our costs, and this unit further reduces the environmental footprint of rare earth production at Mountain Pass," said Molycorp President and CEO Geoff Bedford. "It will play a key role in helping us achieve operating break-even cash flow, before interest, this year." Molycorp did not issue any guidance in its quarterly report. Shares were trading lower by 0.57 percent in the pre-market session. OPKO Health: Misses on revenue Last night, OPKO Health OPK reported its fourth quarter results. The company announced an EPS of -$0.04, beating the consensus estimate of -$0.05. Revenue of $20.7 million missed the consensus estimate of $23.63 million. Net loss for the quarter rose to $16.8 million from $1.1 million in the same quarter last year. The increase in loss was principally related to research and development expenses related to the company's ongoing Phase 3 clinical trials of Raylday and human growth hormone (hGH-CTP) OPKO said that as of December 31 it has $185.8 million in cash and cash equivalents providing the company with liquidity to fund further research and development. Shares were trading higher by 1.81 percent in the pre-market session. Vipshop Holdings: Blowout quarter, strong guidance Last night, Vipshop Holdings VIPS reported its fourth quarter results. The company announced an EPS of $0.49, beating the consensus estimate of $0.41. Revenue of $651 million beat the consensus estimate of $559.43 million. Net income surged by 300 percent to $25.4 million from $6.3 million in the same quarter last year. Gross margin increased to 24.5 percent from 22.9 percent over the same time. Active customers grew by 1.7 million quarter over quarter and 3.1 million year over year. Total orders rose 51 percent quarter over quarter and 102 percent year over year to 17.7 million. Vipshop issued guidance and sees its first quarter revenue to be $640 million to $650 million, well above the consensus estimate of $554.5 million. Shares were trading higher by 23.08 percent in the pre-market session.